Abarelix for injectable suspension: First-in-class gonadotropin-releasing hormone antagonist for prostate cancer

Future Oncology

Volumn 2, Issue 6, 2006, Pages 677-696

  Debruyne, Frans ^a   Bhat, Gajanan ^c   Garnick, Marc B ^b  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b Praecis Pharmaceuticals Incorporated   (United States)

^c NONE

Author keywords

Abarelix androgen deprivation; Gonadotropin releasing hormone antagonist; Hormonal therapy; Luteinizing hormone releasing hormone agonist; Plenaxis ; Prostate cancer; Testosterone flare

Indexed keywords

ABARELIX; ANDROSTANOLONE; ANTIANDROGEN; ATRASENTAN; AVORELIN; BICALUTAMIDE; BUSERELIN; CALCITRIOL; CETRORELIX; D 63153; DEGARELIX; DIETHYLSTILBESTROL; DN 101; DOCETAXEL; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; HISTRELIN; LEUPRORELIN; OSATERONE ACETATE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; PROVENGE; TESMILIFENE; TESTOSTERONE; TEVERELIX; TOREMIFENE; TRIPTORELIN; UNINDEXED DRUG; VAPREOTIDE;

ADJUVANT THERAPY; ADVANCED CANCER; ALLERGIC REACTION; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BACKACHE; BLOOD PRESSURE; BONE METASTASIS; BONE PAIN; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CASTRATION; CATHETER REMOVAL; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE EXACERBATION; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; DRY SKIN; ERYTHEMA; FATIGUE; FOLLITROPIN BLOOD LEVEL; GYNECOMASTIA; HORMONAL THERAPY; HUMAN; HYPERTENSION; IMPOTENCE; INJECTION SITE PAIN; LIVER FUNCTION; LIVER TOXICITY; MACULOPAPULAR RASH; META ANALYSIS; MONOTHERAPY; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEURALGIA; NOCTURIA; NONHUMAN; ORCHIECTOMY; OVERALL SURVIVAL; PAIN; PARESTHESIA; PERIPHERAL EDEMA; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PRURITUS; QT PROLONGATION; RASH; SCROTAL PAIN; SIDE EFFECT; SOMNOLENCE; SPINE METASTASIS; SYNCOPE; SYSTEMATIC REVIEW; TESTIS ATROPHY; TESTIS DISEASE; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE RELEASE; TUMOR FLARE; UNSPECIFIED SIDE EFFECT; URINARY FREQUENCY; URTICARIA; WEIGHT GAIN;

ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUG TOXICITY; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; OLIGOPEPTIDES; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 33845662144     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.2.6.677     Document Type: Article

References (81)

1. Gronberg H: Prostate cancer epidemiology. Lancet 361, 859-864 (2003).
2. Garnick MB, Fair WR: Prostate cancer: emerging concepts. Part I. Ann. Intern. Med. 125, 118-125 (1996).
3. Carroll PR et al. Cancer of the prostate. In: Cancer, Principles And Practice Of Oncology. DeVita VT, Hellman S, Rosenberg SA (Eds). Lippincott, Williams & Wilkins, PA, USA, 1418-1479 (2001).
4. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer statistics, 2006. CA Cancer J. Clin. 56(2), 106-130 (2006).
5. Crawford ED, Eisenberger MA, McLeod DG et al.: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 321, 419-424 (1989).
6. Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD: Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and (4128) patients using flutamide. Prostate Cancer Prostatic Dis. 2, 4-8 (1999).
7. Denis LJ, Keuppens F, Smith PH et al.: Maximal androgen blockade: final analysis of EORTC Phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur. Urol. 33, 144-151 (1998).
8. Kuhn JM, Billebaud T, Navratil H et al.: Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N. Engl. J. Med. 321, 413-418 (1989).
9. Bubley GJ: Is the flare phenomenon clinically significant? Urology 58, 5-9 (2001).
10. Tomera K, Gleason D, Gittelman M et al.: The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies inpatients with prostate cancer. J. Urol. 165, 1585-1589 (2001).
11. Garnick MB, Campion M: Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group. Mol. Urol. 4, 275-277 (2000).
12. Cook T, Sheridan WP: Development of GnRH antagonists for prostate cancer: new approaches to treatment. Oncologist 5, 162-168 (2000).
13. Weckermann D, Harzmann R: Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur. Urol. 46, 279-284 (2004).
14. Praecis Pharmaceuticals Incorporated. Plenaxis (abarelix for injectable suspension) (Prescribing information). Praecis Pharmaceuticals Incorporated, Waltham, MA, USA (2004).
15. Hellerstedt BA, Pienta KJ: The current state of hormonal therapy for prostate cancer. CA Cancer J. Clin. 52, 154-179 (2002).
16. Karten MJ, Rivier JE: Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr. Rev. 7, 44-66 (1986).
17. Huirne JA, Lambalk CB: Gonadotropin-releasing-hormone-receptor antagonists. Lancet 358, 1793-1803 (2001).
18. ALZA Corporation: Viadur (package insert). ALZA Corporation; distributed by Bayer Corporation Pharmaceutical Division, Mountain View, CA, USA (2002).
19. AstraZeneca Pharmaceuticals: Zoladex 3.6 mg (package insert). AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA (2003).
20. TAP Pharmaceuticals: Lupron Depot 7.5 mg (package insert). TAP Pharmaceuticals Inc., Lake Forest, IL, USA (2003).
21. Thompson IM, Zeidman EJ, Rodriguez FR: Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J. Urol. 144, 1479-1480 (1990).
22. Debruyne F: Hormonal therapy of prostate cancer. Semin. Urol. Oncol. 20, 4-9 (2002).
23. Leuprolide Study Group: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N. Engl. J. Med. 311, 1281-1286 (1984).
24. Bruchovsky N, Goldenberg SL, Akakura K, Rennie PS: Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol. Cancer 72, 1685-1691 (1993).
25. Kolvenbag GJ, Iversen P, Newling DW: Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer. Urology 58, 16-23 (2001).
26. Wysowski DK, Freiman JP, Tourtelot JB, Horton ML III: Fatal and nonfatal hepatotoxicity associated with flutamide. Ann. Intern. Med. 118, 860-864 (1993).
27. Denmeade SR, Isaacs JT: Development of prostate cancer treatment: the good news. Prostate 58, 211-224 (2004).
28. Wong SL, Lau DT, Baughman SA, Fotheringham N, Menchaca D, Garnick MB: Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. J. Clin. Pharmacol. 44, 495-502 (2004).
29. Selvaggi FP, Khoe GSS, Van Cangh P et al.: Comparison of abarelix depot (A-D) and goserelin (G) plus bicalutamide (B) in advanced prostate cancer: results of a multicentre, open-label, randomized, Phase III study (abstract). Presented at: 16th Congress of the European Association of Urology. Geneva, Switzerland, April 7-10 (2001). Eur. Urol. 39(Suppl. 5), S78 (2001).
30. McLeod D, Zinner N, Tomera K et al.: A Phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 58, 756-761 (2001).
31. Trachtenberg J, Girdeman M, Steidle C et al.: A Phase 3, multicenter, open label, randomized study of abaretix versus leuprolide plus daily antiandrogen in men with prostate cancer. J. Urol. 167, 1670-1674 (2002).
32. Koch M, Steidle C, Brosman S et al.: An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists. Urology 62, 877-882 (2003).
33. Wong SL, Lau DT, Baughman SA, Menchaca D, Gafnick MB: Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer. Clin. Pharmacol. Ther. 73, 304-311 (2003).
34. Ben Josef E, Yang SY, Ji TH et al.: Hormone-refiactory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J. Urol. 161, 970-976 (1999).
35. Beer TM, Garzotto M, Eilers KM, Lemmon D: Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy. J. Urol. 169, 1738-1741 (2003).
36. Beer TM, Garzotto M, Eilers KM, Lemmon D, Wersinger EM: Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy Urology 63, 342-347 (2004).
37. Wagner M, Garzotto M, Lemmon D, Eilers KM, Beer TM: Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer. Urology 65, 799 (2005).
38. Huhtaniemi I, Venho P, Jacobi G, Rannikko S: Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer. J. Androl, 12, 46-53 (1991).
39. Mahler C, Verhelst J, Chaban M, Denis L: Prolactin and Pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue. Cancer 67, 557-559 (1991).
40. Khan MS, O'Brien A: An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate. Urol, Int. 60, 33-40 (1998).
41. Praecis Pharmaceuticals Incorporated. Abarelix for injectable suspension: integrated surnmary of risks and benefit (data on file). Praecis Pharmaceuticals Incorporated, Waltham, MA, USA (2003).
42. Praecis Pharmaceuticals Incorporated. Abarelix for injectable suspension: integrated summary of safety (data on file). Praecis Pharmaceuticals Incorporated, Waltham, MA, USA (2003).
43. Praecis Pharmaceuticals Incorporated. Abarelix for injectable suspension: clinical study report: ABACAS 1 (data on file). Praecis Pharmaceuticals Incorporated, Waltham, MA, USA (2003).
44. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH: Timing of new black box warnings and withdrawals for prescription medications. JAMA 287, 2215-2220 (2002).
45. Roden DM: Drug-induced prolongation o the QT interval. N. Engl. J. Med. 350, 1013-1022 (2004).
46. Garnick MB, Pratt C, Campion M, Shipley J, Bernady J: Increase in the electrocardiographic QTc interval in med with prostate cancer undergoing androgen deprivation therapy: results of three randomized controlled clinical studies. Presented at: European Association of Urology 19th Congress Vienna, Austria, March 24-27 (2004) (Abstract).
47. Garnick MB, Pratt C, Campion M, Shipley J: The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: Phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix. Presented at: ASCO Annual Meeting 2004. J Clin. Oncol. 22(14S), S401 (2004) (Abstract).
48. Debruyne FM: ABACAS 1, a comparison of the efficacy and safety of abarelix versus goserelin plus bicalutamide in patients with advanced or metastatic prostate cancer: a one year randomized open-label multicenter, Phase III trial. Presented by P Teillac at: Advances in the Biology of Hormonal Therapy in the Treatment of Prostate Cancer. European Association of Urology 18th Congress, Madrid, Spain (2003) (Abstract).
49. Stoch SA, Parker RA, Chen L et al.: Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J. Clin. Endocrinol. Metab. 86, 2787-2791 (2001).
50. Miyaji Y, Saika T, Yamamoto Y et al.: Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer. Urology 64, 128-131 (2004).
51. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J. Urol, 169, 2008-2012 (2003).
52. Saad F, Schulman CC: Role of bisphosphonates in prostate cancer. Eur. Urol. 45, 26-34 (2004).
53. Balchen T, Agerso H et al.: Single subcutaneous administration of a novel, fast-acting gonadotropin-releasing hormone antagonist degarelix (FE200486) with depot characteristics in healthy men. Clin. Exp. Pharmacol. Physiol, 31 (Suppl. 1) (2004).
54. Weston P, Hammonds J, Vaughton K et al: Degarelix: a novel GnRH antagonist tested in a multicenter, randomized, dose-finding study in prostate cancer patients: (podium presentation, no.PD-4.03). Presented at: 27th Congress of the Societe Internationale d'Urologie. October 5, Hawaii, USA (2004).
55. Lorenzo A: Spectrum deals for rights to clinical-stage LHRH antagonist. Bioworld Today 15, (2004).
56. Erb K, Pechstein B, Schueler A, Engel J, Hermann R: Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men - a first-dose-in-humans study. Clin. Pharmacol. Ther. 67, 660-669 (2000).
57. Jungwirth A, Pinski J, Galvan G et al.: Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II: Eur. J. Cancer 33, 1141-1148 (1997).
58. Kaisary AV, Bowsher WG, Gillatt DA, Anderson JB, Malone PR, Imbimbo BP: Pharmacodynamics of a long acting depot preparation of avorelin in patients with prostate cancer. Avorelin Study Group. J. Urol. 162, 2019-2023 (1999).
59. Chertin B, Spitz IM, Lindenberg T et al.: An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer. J. Urol. 163, 838-844 (2000).
60. Schlegel PN, Kuzma P, Frick J et al.: Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin. Urology 58, 578-582 (2001).
61. Teillac P, Heyns CF, Kaisary AV, Bouchot O, Blumberg J: Pharmacodynamic equivalence of a decapeptyl 3-month SR formulation with the 28-day SR formulation in patients with advanced prostate cancer. Horm. Res. 62, 252-258 (2004).
62. Kelly G, Edwards M: Interim results of a phase Ib/IIa study of oral phenoxodiol in patients with late-stage, hormone-refractory prostate cancer. Presented at: 95th Annual Meeting of the American Association for Cancer Research: late breaker abstracts 103-104, (2004).
63. Mieda M, Ohta Y, Saito T, Takahashi H, Shimazawa E, Miyasaka K: Antiandrogenic activity and endocrinological profile of a novel antiandrogen, TZP-4238, in the rat. Endocr. J. 41, 445-452 (1994).
64. Shukeir N, Arakelian A. Chen G et al.: A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia. Cancer Res. 64, 5370-5377 (2004).
65. Shukeir N, Arakelian A, Kadhim S et al.: Prostate secretory Protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Res. 63, 2072-2078 (2003).
66. Brandes LJ, Bracken SP: The intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethamine. HCL, may potentiate doxorubicin in the treatment of metastatic breast cancer: Results of a pilot study. Breast Cancer Res. Treat. 49, 61-68 (1998).
67. Brandes LJ, Bracken SP, Ramsey EW: N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine in combination with cyclophosphamide: an active, low-toxicity regimen for metastatic hormonally unresponsive prostate cancer. J. Clin. Oncol. 13, 1398-1403 (1995).
68. Brandes LJ, LaBella FS, Warrington RC: Increased therapeutic index of antineoplastic drugs in combination with intracellular histamine antagonists. J. Natl. Cancer Inst. 83, 1329-1336 (1991).
69. Brandes LJ, Hogg GR: Study of the in-vivo antioestrogenic action of N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine HCI (DPPE), a novel intracellular histamine antagonist and antioestrogen binding site ligand. J. Reprod. Fertil. 89, 59-67 (1990).
70. Raghavan D, Brandes KK, Snyder T et al: Mitoxantrone plus DPPE in hormone-refractory prostate cancer (HR-CAP) with symptomatic metastases - response in 70% of cases: American Society of Clinical Oncology Annual Meeting. (2002) (Abstract 786).
71. Stein S, Zoltick B, Peacock T et al: Phase II trial of toremifene in androgen-independent prostate cancer: a Penn cancer clinical trials group trial. Am. J. Clin. Oncol. 24,283-285 (2001).
72. Steiner MS, Pound CR: Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia. Clin. Prostate Cancer 2, 24-31 (2003).
73. Beer TM, Javle M, Henner W, Trump D: Pharmcokinetics (PK) and tolerability of DN- 101, a new formulation of calcitriol, in patients with cancer. Presented at: American Association for Cancer Research Annual Meeting. Orlando, FL, USA (2004) (Abstract).
74. Beef TM: Development of weekly high-dose calcitriol based therapy for prostate cancer. Urol. Oncol. 21, 399-405 (2003).
75. Beer TM, Myrthue A: Calcitriol in cancer treatment: from the lab to the clinic. Mol. Cancer Ther. 3, 373-381 (2004).
76. Beer TM, Eilers KM, Garzotto M, Hsieh YC, Mori M: Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma. Cancer 100, 758-763 (2004).
77. Gonzalez-Barcena D, Schally AV, Vadillo-Buenfil M et al.: Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse. Prostate 56, 183-191 (2003).
78. Pinski J, Schally AV, Halmos G, Szepeshazi K: Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice. Int. J. Cancer 55, 963-967 (1993).
79. Pollak MN, Schally AV: Mechanisms of antineoplastic action of somatostatin analogs. Proc. Soc. Exp. Biol. Med. 217, 143-152 (1998).
80. Carducci MA. Padley RJ, Breul J et al: Effect of endothelin-A receptor blockade with atrasentan on turnor progression in men with hormone-refractory prostate cancer: a randomized, Phase II, placebo-controlled trial. J. Clin. Oncol. 21, 679-689 (2003).
81. Carducci MA, Nelson JB et al.: Effects of altrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: Phase 3 study (abstract). American Society of Clinical Oncology, 40th Annual Meeting (2004) (Abstract).